Third generation aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane have demonstrated a longer disease-free survival, and better overall safety in the adjuvant treatment of postmenopausal women with ER-positive BC, compared with the selective ER modulator (SERM) Tamoxifen (TAM) [2,3]. Here, ESR1 is linked to breast cancer.